NCT01690468 - PTX-200 and Carboplatin in Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Ovarian Cancer

Interventions

DRUG

Triciribine

Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.

DRUG

Carboplatin

Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa